This will be an open label, sequential study of midazolam (dose 5 mg orally) followed by
midazolam (5 mg orally) given after dosing with OC000459 100 mg twice daily for 6.5 days.
Twenty subjects will be included to ensure at least 16 subjects with analysable PK data. PK
sampling for midazolam and 4-hydroxymidazolam plasma concentrations will continue for up to
and including 24 hours after dosing with midazolam on both occasions.